BSX Boston Scientific Corp

Price (delayed)

$73.01

Market cap

$107.11B

P/E Ratio

67.6

Dividend/share

N/A

EPS

$1.08

Enterprise value

$115.35B

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, ...

Highlights
The EPS has soared by 140% YoY and by 32% from the previous quarter
Boston Scientific's net income has surged by 128% YoY and by 30% QoQ
BSX's quick ratio is down by 17% year-on-year and by 6% since the previous quarter
Boston Scientific's debt has increased by 2.3% QoQ

Key stats

What are the main financial stats of BSX
Market
Shares outstanding
1.47B
Market cap
$107.11B
Enterprise value
$115.35B
Valuations
Price to book (P/B)
5.55
Price to sales (P/S)
7.45
EV/EBIT
51.24
EV/EBITDA
33.46
EV/Sales
8.1
Earnings
Revenue
$14.24B
EBIT
$2.25B
EBITDA
$3.45B
Free cash flow
$1.83B
Per share
EPS
$1.08
Free cash flow per share
$1.26
Book value per share
$13.16
Revenue per share
$9.8
TBVPS
$10.15
Balance sheet
Total assets
$35.14B
Total liabilities
$15.61B
Debt
$9.1B
Equity
$19.28B
Working capital
$1.58B
Liquidity
Debt to equity
0.47
Current ratio
1.32
Quick ratio
0.63
Net debt/EBITDA
2.39
Margins
EBITDA margin
24.2%
Gross margin
69.5%
Net margin
11.2%
Operating margin
16.5%
Efficiency
Return on assets
4.6%
Return on equity
8.5%
Return on invested capital
12.5%
Return on capital employed
7.5%
Return on sales
15.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BSX stock price

How has the Boston Scientific stock price performed over time
Intraday
5.83%
1 week
7.43%
1 month
7.97%
1 year
42.21%
YTD
26.29%
QTD
6.6%

Financial performance

How have Boston Scientific's revenue and profit performed over time
Revenue
$14.24B
Gross profit
$9.9B
Operating income
$2.34B
Net income
$1.59B
Gross margin
69.5%
Net margin
11.2%
Boston Scientific's net income has surged by 128% YoY and by 30% QoQ
Boston Scientific's net margin has surged by 104% YoY and by 26% QoQ
Boston Scientific's operating income has increased by 42% YoY and by 9% from the previous quarter
BSX's operating margin is up by 27% year-on-year and by 5% since the previous quarter

Growth

What is Boston Scientific's growth rate over time

Valuation

What is Boston Scientific stock price valuation
P/E
67.6
P/B
5.55
P/S
7.45
EV/EBIT
51.24
EV/EBITDA
33.46
EV/Sales
8.1
The EPS has soared by 140% YoY and by 32% from the previous quarter
The P/E is 13% below the last 4 quarters average of 73.2 and 11% below the 5-year quarterly average of 71.9
The stock's price to book (P/B) is 31% more than its 5-year quarterly average of 4.0 and 25% more than its last 4 quarters average of 4.2
The equity has grown by 10% YoY and by 2.1% from the previous quarter
BSX's P/S is 33% above its 5-year quarterly average of 5.3 and 24% above its last 4 quarters average of 5.7
The revenue has increased by 12% YoY and by 3.5% from the previous quarter

Efficiency

How efficient is Boston Scientific business performance
The return on assets has surged by 130% year-on-year and by 28% since the previous quarter
The return on equity has surged by 130% year-on-year and by 29% since the previous quarter
BSX's ROIC is up by 37% YoY and by 5% from the previous quarter
The ROS has increased by 24% YoY

Dividends

What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BSX.

Financial health

How did Boston Scientific financials performed over time
Boston Scientific's total assets is 125% more than its total liabilities
BSX's quick ratio is down by 17% year-on-year and by 6% since the previous quarter
BSX's current ratio is down by 13% year-on-year and by 7% since the previous quarter
Boston Scientific's debt is 53% lower than its equity
The equity has grown by 10% YoY and by 2.1% from the previous quarter
Boston Scientific's debt to equity has decreased by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.